This article was originally published here
Ann Allergy Asthma Immunol. 2021 May 7:S1081-1206(21)00337-9. doi: 10.1016/j.anai.2021.04.029. Online ahead of print.
OBJECTIVE: To present a comprehensive, clinically focused scoping review of therapeutic agents and practices comprising the future of allergic rhinitis (AR) management.
DATA SOURCES: A review of the published literature was performed using the PubMed database, published abstracts and virtual presentations from scientific meetings, and posted results on ClinicalTrials.gov.
STUDY SELECTIONS: Primary manuscripts with trial results, case reports, case series and clinical trial data from ClinicalTrials.gov, PubMed and articles highlighting expert perspectives on management of AR were selected.
RESULTS: Telemedicine, social media, and mHealth facilitate integrated care for AR management. Pharmacotherapy remains the standard of care for AR management, however, treatment combinations are recommended. Intralymphatic immunotherapy (ILIT) and peptide immunotherapy (PIT) are the most promising new allergen immunotherapy options . Studies of targeted biologics for AR are ongoing. Probiotics may be beneficial for AR management, particularly Bifidobacterium spp, and as an add-on to allergen immunotherapy (AIT).
CONCLUSION: AR is a chronic and often comorbid condition that requires integrated care for optimal management. New formulations and combinations of existing AR therapies are the most promising and merits future research.